FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 32350104

Estimated average burden
hours per
response: 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person Hulls Chris	Requirin	g Statement Day/Year)	3. Issuer Name and Ticker or Trading Symbol Life360, Inc. [360.AX]							
(Last) (First) (Middle) C/O LIFE360, INC. 539 BRYANT STREET, SUITE 402 (Street) SAN FRANCISCO CA 94107 (City) (State) (Zip)	2		4. Relationship of Reporting Person(s Issuer (Check all applicable) X Director 10% C X Officer (give title below) below) Chief Executive Officer		% Ov ner (s ow)	Owner 6. (C)		5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person		
	Table I - No	on-Deriva	tive Securities Ben	eficially	Ow	ned				
1. Title of Security (Instr. 4)			2. Amount of Securities Beneficially Owned (Ins 4)	str. Forr	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)		4. Nature of Indirect Beneficial Ownership (Instr. 5)			
Common Stock			3,031,429(1)		D					
Common Stock			29,960(2)		I		Held by ICCA Labs, LLC ⁽³⁾			
(€			e Securities Benef ants, options, conv							
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)			4. Conversion or Exercise		5. Ownership Form:	6. Nature of Indirect Beneficial	
	Date Exercisable	Expiration Date	Title	Amount Number Shares		Price of Derivative Security		Direct (D) or Indirect (I) (Instr. 5)	Ownership (Instr. 5)	
Stock Option (right to buy)	(4)	10/24/2027	Common Stock	208,98	37	2.15		D		
Stock Option (right to buy)	(5)	07/16/2028	Common Stock	1,269,3	886	2.53		D		
Stock Option (right to buy)	(4)	10/30/2028	Common Stock	10		9.55		D		
Stock Option (right to buy)	(6)	07/30/2030	Common Stock	230,00	00	7.28		D		
Stock Option (right to buy)	(7)	02/01/2031	Common Stock	100,00	00	13.35		D		
Stock Option (right to buy)	(8)	05/20/2032	Common Stock	204,57	73	8.19		D		

Explanation of Responses:

- 1. Includes 1,686,552 shares of the Issuer's common stock underlying 5,059,656 Chess Depositary Interests ("CDIs"). The CDIs are traded on the Australian Securities Exchange (the "ASX") and are held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Also includes 103,596 restricted stock units, each of which represents a contingent right to receive one share of the Issuer's common stock upon vesting.
- 2. Represents shares of the Issuer's common stock underlying 89,880 CDIs.
- 3. The Reporting Person is a member of ICCA Labs, LLC, an entity that holds an aggregate of 133,408 shares of the Issuer's common stock underlying 400,224 CDIs. The number of shares reported herein by the Reporting Person represents his proportionate ownership interest in ICCA Labs, LLC.
- 4. The stock option is fully vested and exercisable.
- 5. The stock option vests and becomes exercisable as to 1/48th of the total number of shares in equal monthly installments beginning on August 16, 2018, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
- 6. The stock option vests and becomes exercisable as to 1/48th of the total number of shares in equal monthly installments beginning on August 30, 2020, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
- 7. The stock option vests and becomes exercisable as to 1/48th of the total number of shares in equal monthly installments beginning on March 1, 2021, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
- 8. The stock option vests and becomes exercisable as to 1/48th of the total number of shares in equal monthly installments beginning on February 1, 2022, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

Remarks:

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

The undersigned as a Section 16 reporting person of Life360, Inc. (the "Company"), hereby constitutes and appoints Russell J. Burke, Kirsten Daru and Daniel Menudier, and each of them, the undersigned's true and lawful attorney-in-fact to:

- (1) execute, deliver and file for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of the Company, Forms 3, 4, and 5 in accordance with Section 16(a) of the Exchange Act;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority;
- (3) seek or obtain, as the undersigned's representative and on the undersigned's behalf, information on transactions in the Company's securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to the undersigned and approves and ratifies any such release of information; and
- (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act. The undersigned further acknowledges and agrees that the attorney-in-fact and the Company are relying on written and oral information provided by the undersigned to complete such forms and the undersigned is responsible for reviewing the completed forms prior to their filing. The attorney-in-fact and the Company are not responsible for any errors or omissions in such filings. The attorney-in-fact and the Company are not responsible for determining whether or not the transactions reported could be matched with any other transactions for the purpose of determining liability for short-swing profits under Section 16(b).

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of 5/25/2022.

/s/ Chris Hulls

Name: Chris Hulls